mesalamine 1.2 g

1 INDICATIONS AND USAGE Mesalamine delayed-release tablets are indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg. Mesalamine delayed-release tablets are an aminosalicylate indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. ( 1 ) treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg. (1)

lannett company inc.

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] off label use` `[3] nausea` `[4] fatigue` `[5] diarrhoea` `[6] weight increased` `[7] dyspnoea` `[8] vomiting` `[9] condition aggravated` `[10] anxiety`

4 months ago

OVAL PINK SI

4 months ago

SI OVAL PINK

16 HOW SUPPLIED/STORAGE AND HANDLING

MESALAMINE delayed-release tablets, USP are available as light red to red, oval, bi-convex, film-coated, with ‘S1’ debossed on one side and plain on the reverse side. NDC 0527-3012-48 HDPE Bottle with a child-resistant closure of 120 delayed-release tablets. Store at 20ºC to 25ºC (68ºF to 77ºF); excursions permitted to 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature.

More pills like OVAL SI

Related Pills

Singulair 10 MG Oral Tablet

Merck Sharp & Dohme Corp.

Stribild cobicistat 150 MG elvitegravir 150 MG emtricitabine 200 MG Tenofovir disoproxil fumarate 300 Oral Tablet

Gilead Sciences, Inc.

Ranexa 12 HR ranolazine 1000 MG Extended Release Oral Tablet Ranexa

Gilead Sciences, Inc.

panadol extra strength acetaminophen tablet film coated panadol extra strength acetaminophen tablet

glaxosmithkline consumer healthcare holdings

cobicistat 150 MG elvitegravir 150 MG emtricitabine 200 MG tenofovir alafenamide 10 MG Oral Tablet Genvoya

gilead sciences, inc.

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site